Revenue
375 thousand
2020 Q4 ·
Fundies. English
LEAP THERAPEUTICS, INC.
EDGAR76 filing records in this dataset, filed from 2016-09-26 to 2026-08-12. Reported financial figures are available; chart coverage varies by period.
Latest quarter
- Cash and cash equivalents
- 7.62 million Unit_Standard_USD_w-mAaMAs6kSDuSFskmBY4A Source
Exact value
7624000 Unit_Standard_USD_w-mAaMAs6kSDuSFskmBY4A
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 108 million Unit_Standard_shares_ctVDT-OO8k6h-kCYHvfhwg Source
Exact value
107764382 Unit_Standard_shares_ctVDT-OO8k6h-kCYHvfhwg
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-08-12.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: Multiple units; comparison withheld· newest 2021-12-31
- Operating income: 2 of 11 periods available· newest 2025-12-31
- Net income: 2 of 11 periods available· newest 2025-12-31
- Operating cash flow: 2 of 11 periods available· newest 2025-12-31
- Capital expenditure: 3 of 11 periods available· newest 2019-12-31
- Total assets: Multiple units; comparison withheld· newest 2025-12-31
- Total liabilities: Multiple units; comparison withheld· newest 2025-12-31
- Current assets: Multiple units; comparison withheld· newest 2025-12-31
- Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
- Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: Multiple units; comparison withheld· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
+Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg 72.38 millionPrior period
−Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg 67.56 million
–
Current period
Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg 4.82 million
–
Exact inputs and evidence
4822000 − -67555000 = 72377000 Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg
-67555000 Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg · 2024-01-01 – 2024-12-31
Inspect prior input Prior source4822000 Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg 16.4 millionPrior period
−Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg 60.3 million
–
Current period
−Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg 43.9 million
–
Exact inputs and evidence
-43902000 − -60299000 = 16397000 Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg
-60299000 Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-43902000 Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2024 2024-01-01 – 2024-12-31 | −Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg 67.56 million Exact valueExact value: -67555000 Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg 2024-01-01 – 2024-12-31: -67555000 Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg Inspect Net Income Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | −Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg 60.3 million Exact valueExact value: -60299000 Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg 2024-01-01 – 2024-12-31: -60299000 Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg Inspect Operating Cash Flow Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg 4.82 million Exact valueExact value: 4822000 Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg 2025-01-01 – 2025-12-31: 4822000 Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg Inspect Net Income Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | −Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg 43.9 million Exact valueExact value: -43902000 Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg 2025-01-01 – 2025-12-31: -43902000 Unit_Standard_USD_5o8g6GRxm0SGjoGE8SH2Xg Inspect Operating Cash Flow Open source Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
76 filings · 3,168 latest values · 3,168 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001509745, 1509745, CYPH, LPTX, edgar:1509745
Also known as CYPHERPUNK TECHNOLOGIES INC., Dekkun Corp, LEAP THERAPEUTICS, INC., LEAP THERAPEUTICS, INC.